As of 4:00pm ET
| +0.04 / +0.88%|
The 7 analysts offering 12-month price forecasts for Keryx Biopharmaceuticals Inc have a median target of 7.00, with a high estimate of 9.00 and a low estimate of 5.00. The median estimate represents a +53.17% increase from the last price of 4.57.
The current consensus among 7 polled investment analysts is to Buy stock in Keryx Biopharmaceuticals Inc. This rating has held steady since April, when it was upgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.